Serum level of IL-17, as a pro-inflammatory cytokine, is higher in patients with psoriasis. Additionally, treatment of psoriasis with topical medications reduce serum level of IL-17. interleukin-17 psoriasis
Conditions
Interventions
Patients with psoriasis referred to dermatology clinic at Sina hospital of Hamadan, were selected based on definite clinical and pathological criteria. ,Healthy subjects (the control group) were selec
Treatment,Treatment
Psoriatic patients,Healthy controls
Sponsors
Hamadan University of Medical sciences
Eligibility
Sex/Gender
All
Age
28 Years to 72 Years
Inclusion criteria
Inclusion criteria: Patients with psoriasis referred to dermatology clinic were selected based on definite clinical and pathological criteria. The patients should have active psoriatic skin lesions and a history of disease, without recent use of topical or systemic corticosteroid in the last three months. Healthy subjects (the control group) were selected from non-familial companions referred to the clinic if they had no history of autoimmune or inflammatory diseases.
Exclusion criteria
Exclusion criteria: Subjects with a history of concomitant autoimmune or inflammatory diseases, as well as pregnant or lactating women were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease severity 4 weeks PASI (Psoriasis Area and Severity Index) | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Iran
Contacts
Public ContactHamid Reza Ghasemi Basir
Psoriasis Research Center, Hamadan University of Medical sciences, Hamadan, Iran
Outcome results
None listed